Waters Corporation (WAT) fair value analysis

S&P 500 · Updated 2026-09-07

Waters Corporation is a manufacturer and provider of laboratory instruments, software, and services used for chemical analysis and testing across various industries including pharmaceuticals, food and beverage, environmental monitoring, and academic research. The company operates globally with a presence in multiple countries across North America, Europe, Asia, and other regions.

Forward Fair Value verdict

Fairly valued

Based on TickrTrends' weekly Forward Fair Value model, WAT is trading at within about 10% of estimated fair value.

WAT currently ranks #61 of 113 Healthcare stocks by discount to Forward Fair Value. It has screened as Fairly valued for 3 consecutive weekly runs.

Last price: $409.38
Sector: Healthcare
12-month range: $299.89–$405.84

Derived indicators

Coarse bands from TickrTrends' weekly models; exact figures are part of the full report.

Quality grade: D
Leverage: Moderate
Margin trend: Stable
Revenue growth: Modest
RSI zone: Neutral
52-week position: The top quarter of its range

What our data shows for WAT

Our model validated 17 trailing price-to-earnings windows for WAT, built from quarterly earnings records.
Shares are trading in the upper third of their 12-month price range of $299.89–$405.84.
The 14-day relative strength index sits at a neutral 53.

The exact numbers are one step away

The precise Forward Fair Value dollar figure for WAT
Exact discount / premium to today's price
The normalized historical P/E behind the estimate, and how many quarters support it
Forward EPS input and fiscal-year basis
Screeners and rankings across the full S&P 500 and Nasdaq universes

See the exact fair value →

How Forward Fair Value works

TickrTrends computes a Forward Fair Value for every covered stock each week: a conservatively normalized historical price-to-earnings multiple is applied to the analyst-consensus earnings estimate for the next full fiscal year. Every input window is validated for continuity and every result is screened for plausibility before publication.

Recent WAT news

TickrTrends' derived news-sentiment signal for WAT is currently leaning positive, computed from recent coverage.

WAT Looks 2.4% Overvalued on GF Value™ as Piper Sandler Boosts Price Target (gurufocus.com, 2026-08-27)
TickrTrends take: Waters Corporation operates in the Healthcare sector and currently holds a Fairly valued designation according to TickrTrends analysis. The recent analyst action from Piper Sandler represents a positive development that contrasts with the GF Value assessment suggesting modest overvaluation, creating a divergence that investors monitoring valuation metrics should track closely. For those focused on valuation fundamentals, this gap between analyst enthusiasm and intrinsic value estimates warrants observation as new data emerges.

What people are saying

Follow the WAT conversation: Stocktwits · Reddit · X

TickrTrends weekly updates

2026-09-07 — No material change this week: the verdict, bands and grades all held steady.
2026-09-06 — TickrTrends' derived indicators for WAT showed notable changes this week. The DCF cross-check band moved from an overvalued reading to none, while the momentum indicator, which had registered at A, is no longer displaying a value. The current valuation verdict for the Healthcare sector company remains fairly valued.
2026-08-31 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.

Frequently asked questions

Is WAT stock undervalued?

Based on TickrTrends' Forward Fair Value model (updated 2026-09-07), WAT is trading at within about 10% of estimated fair value and screens as fairly valued. The exact fair value and discount are available to subscribers.

What is WAT's TickrTrends verdict?

WAT's current verdict is Fairly valued, refreshed with every weekly Forward Fair Value run.

How does WAT compare to other Healthcare stocks?

WAT ranks #61 of 113 Healthcare stocks in TickrTrends' coverage when sorted by discount to Forward Fair Value.

Is WAT overbought or oversold?

WAT's 14-day RSI is in neutral territory - neither overbought nor oversold.

All Healthcare fair-value coverage →

Head-to-head comparisons

WAT vs A · WAT vs BAX · WAT vs DHR · WAT vs ENSG · WAT vs INVA